Next Article in Journal
Active Surveillance for Prostate Cancer: Patient Selection and Management
Previous Article in Journal
Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue s1
10.3747/co.v17is1.614
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies

by
D. Soulières
1,
W. Greer
2,
Anthony M. Magliocco
3,
D. Huntsman
4,
S. Young
4,
M.-S. Tsao
5 and
Suzanne Kamel-Reid
5,*
1
Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
2
Department of Pathology, Dalhousie University, Halifax, NS, Canada
3
Departments of Oncology, Pathology and Laboratory Medicine, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
4
BC Cancer Agency, Vancouver, BC, Canada
5
University Health Network, Dept. of Pathology, 11 Eaton North, Rm. 213-200 Elizabeth St. Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(s1), 31-40; https://doi.org/10.3747/co.v17is1.614
Submission received: 7 April 2010 / Revised: 5 May 2010 / Accepted: 9 June 2010 / Published: 1 July 2010

Abstract

Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibodies that target the epidermal growth factor receptor (EGFR)—cetuximab and panitumumab—which have demonstrated efficacy in the treatment of mCRC. These therapies are associated with a unique set of toxicities and costs, prompting the need for tools to select patients who are most likely to derive a benefit from them. Mutations in the KRAS oncogene have consistently been shown to predict non-response to cetuximab and panitumumab. The role of KRAS as a marker of efficacy of anti-EGFR therapies is reviewed.
Keywords: KRAS; EGFR; colorectal carcinoma; cetuximab; panitumumab; genetic testing methods KRAS; EGFR; colorectal carcinoma; cetuximab; panitumumab; genetic testing methods

Share and Cite

MDPI and ACS Style

Soulières, D.; Greer, W.; Magliocco, A.M.; Huntsman, D.; Young, S.; Tsao, M.-S.; Kamel-Reid, S. KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies. Curr. Oncol. 2010, 17, 31-40. https://doi.org/10.3747/co.v17is1.614

AMA Style

Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao M-S, Kamel-Reid S. KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies. Current Oncology. 2010; 17(s1):31-40. https://doi.org/10.3747/co.v17is1.614

Chicago/Turabian Style

Soulières, D., W. Greer, Anthony M. Magliocco, D. Huntsman, S. Young, M.-S. Tsao, and Suzanne Kamel-Reid. 2010. "KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies" Current Oncology 17, no. s1: 31-40. https://doi.org/10.3747/co.v17is1.614

Article Metrics

Back to TopTop